S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

OTCMKTS:BRLIUTherapeutics Acquisition Stock Price, Forecast & News

$10.02
+0.04 (+0.40 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.95
Now: $10.02
$10.03
50-Day Range N/A
52-Week Range
$9.90
Now: $10.02
$10.50
Volume11,376 shs
Average Volume56,230 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Brilliant Acquisition Corporation operates as a blank check company. It focuses on acquiring; engaging in share exchange and share reconstruction; purchasing the assets; entering into contractual arrangements; and engaging in similar business combination with one or more businesses. The company was founded in 2019 and is based in Shanghai, China.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Shell Companies
Sub-IndustryN/A
Current SymbolOTCMKTS:BRLIU
CUSIPN/A
CIKN/A
WebN/A
Phone86 21 8012 5497

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
$10.02
+0.04 (+0.40 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BRLIU News and Ratings via Email

Sign-up to receive the latest news and ratings for BRLIU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Therapeutics Acquisition (OTCMKTS:BRLIU) Frequently Asked Questions

Has Therapeutics Acquisition been receiving favorable news coverage?

News headlines about BRLIU stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Therapeutics Acquisition earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Therapeutics Acquisition
.

Who are some of Therapeutics Acquisition's key competitors?

Who are Therapeutics Acquisition's key executives?

Therapeutics Acquisition's management team includes the following people:
  • Dr. Peng Jiang, Chairman, CEO, CFO & Sec. (Age 36)

What is Therapeutics Acquisition's stock symbol?

Therapeutics Acquisition trades on the OTCMKTS under the ticker symbol "BRLIU."

When did the company's quiet period expire?

Therapeutics Acquisition's quiet period expired on Monday, August 3rd. Therapeutics Acquisition had issued 4,000,000 shares in its public offering on June 24th. The total size of the offering was $40,000,000 based on an initial share price of $10.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Therapeutics Acquisition's major shareholders?

Therapeutics Acquisition's stock is owned by many different institutional and retail investors. Top institutional investors include Castle Creek Arbitrage LLC (0.00%).

Which institutional investors are buying Therapeutics Acquisition stock?

BRLIU stock was acquired by a variety of institutional investors in the last quarter, including Castle Creek Arbitrage LLC.

How do I buy shares of Therapeutics Acquisition?

Shares of BRLIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Therapeutics Acquisition's stock price today?

One share of BRLIU stock can currently be purchased for approximately $10.02.

How can I contact Therapeutics Acquisition?

The company can be reached via phone at 86 21 8012 5497.

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.